周超宁;陈军;谷有全;陈江君;党小利;王天红;刘赵东;陈小明;

• 1:兰州大学第一医院
• 2:兰州大学第二医院

摘要(Abstract)：

目的观察帕金森病(Parkinson’s disease,PD)患者血脂、血尿酸(uric acid,UA)水平,明确其与疾病进展的相关性。方法选取兰州大学第一医院156例PD住院患者(PD组)及156例健康体检者(对照组),检测2组血脂、血尿酸水平,对其结果进行分析。结果 PD组甘油三酯(triglyceride,TG)、低密度脂蛋白(low density lipoprotein cholesterol,LDL)、UA水平与对照组相比显著下降,差异均有统计学意义(P<0.01)。男性PD患者TC、TG、HDL、LDL水平均低于女性患者,而UA高于女性患者,差异均有统计学意义(P<0.05)。相关性分析显示,PD组UA及TG与病程均呈负相关(r=-0.169,P=0.035;r=-0.209,P=0.009),与病情严重程度呈负相关,但差异无统计学意义(P>0.05)。结论与正常人相比,PD患者血脂、UA水平降低,低TG、低UA可能是PD发病的危险因素之一。

关键词(KeyWords)： 帕金森病;血脂;血尿酸;甘油三酯;低密度脂蛋白;危险因素;疾病进展

Abstract:

Keywords:

基金项目(Foundation): 甘肃省中医药管理局科研项目(编号:GZK-2018-47)

作者(Authors): 周超宁;陈军;谷有全;陈江君;党小利;王天红;刘赵东;陈小明;

参考文献(References)：

• [1] EUSEBI P,FRANCHINI D,DE GIORGI M,et al.Incidence and prevalence of Parkinson's disease in the Italian egion of Umbria:a population-based study using heathcare administrative databases[J].Neurol Sci,2019,40(8):1709-1712.DOI:10.1007/s10072-019-03872-w.
• [2] ENDERS D,BALZER-GELDSETZER M,RIEDEL O,et al.Prevalence,Duration and Severity of Parkinson's disease in Germany:a combined Meta-analysis from literature data and outpatient samples[J].Eur Neurol,2017,78(3/4):128-136.DOI:10.1159/000477165.
• [3] ZHANG Z X,ROMAN G C,HONG Z,et al.Parkinson's disease in China:prevalence in Beijing,Xian,and Shanghai[J].Lancet,2005,365(9459):595-597.DOI:10.1016/S0140-6736(05)17909-4.
• [4] DORSEY E R,CONSTANTINESCU R,THOMPSON J P,et al.Projected number of people with Parkinson disease in the most populous nations,2005 through 2030[J].Neurology,2007,68(5):384-386.DOI:10.1002/mds.25898.
• [5] MACLEOD A D,TAYLOR K S,COUNSELL C E.Mortality in Parkinson's disease:a systematic review and meta-analysis[J].Mov Disord,2014,29(13):1615-1622.DOI:10.1002/mds.25898.
• [6] WEN M,ZHOU B,CHEN Y H,et al.Serum uric acid levels in patients with Parkinson's disease:A meta-analysis[J].PLoS One,2017,12(3):e0173731.DOI:10.1371/journal.pone.0173731.
• [7] HUANG X,ALONSO A,GUO X,et al.Statins,plasma cholesterol,and risk of Parkinson's disease:a prospective study[J].Mov Disord,2015,30(4):552-559.DOI:10.1002/mds.26152.
• [8] PAUL R,CHOUDHURY A,CHANDRA BORUAH D,et al.Hypercholesterolemia causes psychomotor abnormalities in mice and alterations in cortico-striatal biogenic amine neurotransmitters:Relevance to Parkinson's disease[J].Neurochem Int,2017,108:15-26.DOI:10.1016/j.neuint.2017.01.021.
• [9] GUO X,SONG W,CHEN K,et al.The serum lipid profile of Parkinson's disease patients:a study from China[J].Int J Neurosci,2015,125(11):838-844.DOI:10.3109/00207454.2014.979288.
• [10] WANG A,LIN Y,WU Y,et al.Macronutrients intake and risk of Parkinson's disease:A meta-analysis[J].Geriatr Gerontol Int,2015,15(5):606-616.DOI:10.1111/ggi.12321.
• [11] VIERU E,KOKSAL A,MUTLUAY B,et al.The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease[J].Neurol Sci,2016,37(5):743-747.DOI:10.1007/s10072-015-2471-z.
• [12] JAIN S,TON T G,BOUDREAU R M,et al.The risk of Parkinson disease associated with urate in a community-based cohort of older adults[J].Neuroepidemiology,2011,36(4):223-229.DOI:10.1159/000327748.
• [13] SARKAR S,RAYMICK J,IMAM S,et al.Neuroprotective and Therapeutic Strategies against Parkinson's Disease:Recent Perspectives[J].Int J Mol Sci,2016,17(6):904.DOI:10.3390/ijms17060904.
• [14] SONNINO S,AURELI M,GRASSI S,et al.Lipid rafts in neurodegeneration and neuroprotection[J].Mol Neurobiol,2014,50(1):130-148.DOI:10.1007/s12035-013-8614-4.
• [15] FABELO N,MARTIN V,SANTPERE G,et al.Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease[J].Mol Med,2011,17(9/10):1107-1118.DOI:10.2119/molmed.2011.00119.
• [16] KUBO S,HATANO T,HATTORI N.Lipid rafts involvement in the pathogenesis of Parkinson's disease[J].Front Biosci,2015,20:263-279.DOI:10.2741/4308.
• [17] MARIN R,FABELO N,FERNANDEZ-ECHEVARRIA C,et al.Lipid Raft Alterations in Aged-Associated Neuropathologies[J].Curr Alzheimer Res,2016,13(9):973-984.DOI:10.2174/1567205013666160314150017.
• [18] BERG A L,RAFNSSON A T,JOHANNSSON M,et al.The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids,lipoproteins,and apolipoproteins[J].Metabolism,2006,55(8):1083-1087.DOI:10.1016/j.metabol.2006.04.001.
• [19] GOLDSTEIN D S,HOLMES C,LOPEZ G J,et al.Cardiac sympathetic denervation predicts PD in at-risk individuals[J].Parkinsonism Relat disord,2018,52:90-93.DOI:10.1016/j.parkreldis.2017.10.003.
• [20] ROZANI V,GILADI N,EL-AD B,et al.Statin adherence and the risk of Parkinson's disease:A population-based cohort study[J].PLoS One,2017,12(4):e0175054.DOI:10.1371/journal.pone.0175054.
• [21] YU Z,ZHANG S,WANG D,et al.The significance of uric acid in the diagnosis and treatment of Parkinson disease:An updated systemic review[J].Medicine,2017,96(45):e8502.DOI:10.1097/MD.0000000000 008502.
• [22] CHEN X,BURDETT T C,DESJARDINS C A,et al.Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration[J].Proc Natl Acad Sci U S A,2013,110(1):300-305.DOI:10.1073/pnas.1217296110.
• [23] GAO J,HUANG X,PARK Y,et al.Apolipoprotein E genotypes and the risk of Parkinson disease[J].Neurobiol Aging,2011,32(11):2106.e1-2106.e6.DOI:10.1016/j.neurobiolaging.2011.05.016.
• [24] JOHANSEN C T,WANG J,LANKTREE M B,et al.An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia[J].Arterioscl Thromb Vasc Biol,2011,31(8):1916-1926.DOI:10.1161/ATVBAHA.111.226365.
• [25] HUANG X,ABBOTT R D,PETROVITCH H,et al.Low LDL cholesterol and increased risk of Parkinson's disease:prospective results from Honolulu-Asia Aging Study[J].Mov Disord,2008,23(7):1013-1018.DOI:10.1002/mds.22013.
• [26] BEAL M F,OAKES D,SHOULSON I,et al.A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease:no evidence of benefit[J].JAMA Neurol,2014,71(5):543-552.DOI:10.1001/jamaneurol.2014.131.
• [27] KAIKKONEN J,NYYSSONEN K,TUOMAINEN T P,et al.Determinants of plasma coenzyme Q10 in humans[J].FEBS Lett,1999,443(2):163-166.DOI:10.1016/s0014-5793(98)01712-8.
• [28] 郭芬,王晓雪,许宏侠,等.老年帕金森病血清生化指标与非运动症状的关系[J].中国实用神经疾病杂志,2020,23(13):1131-1135.DOI:10.12083/SYSJ.2020.13.257.
• [29] GUDALA K,BANSAL D,MUTHYALA H.Role of serum cholesterol in Parkinson's disease:a meta-analysis of evidence[J].J Parkinson's Dis,2013,3(3):363-370.DOI:10.3233/JPD-130196.
• [30] VIKDAHL M,BACKMAN L,JOHANSSON I,et al.Cardiovascular risk factors and the risk of Parkinson's disease[J].Eur J Clin Nutr,2015,69(6):729-733.DOI:10.1038/ejcn.2014.259.
• [31] 杨凌飞,刘爱华,耿一萌,等.早期帕金森病患者脑脊液生物标志物及炎症因子水平的研究[J].中国实用神经疾病杂志,2019,22(3):267-272.DOI:10.12083/SYSJ.2019.03.051.
• [32] 冯斌.血脂、胱抑素C、同型半胱氨酸与帕金森病及其亚型的相关性[D].兰州:兰州大学,2017.
• [33] JESUS S,PEREZ I,CACERES-REDONDO M T,et al.Low serum uric acid concentration in Parkinson's disease in southern Spain[J].Eur J Neurol,2013,20(1):208-210.DOI:10.1111/j.1468-1331.2012.03745.x.
• [34] SHEN C,GUO Y,LUO W,et al.Serum urate and the risk of Parkinson's disease:results from a meta-analysis[J].Can J Neurol Sci,2013,40(1):73-79.DOI:10.1017/s0317167100012981.
• [35] WANG L,HU W,WANG J,et al.Impact of serum uric acid,albumin and their interaction on Parkinson's disease[J].Neurol Sci,2017,38(2):331-336.DOI:10.1007/s10072-016-2738-z.